Using a Type of Blood Pressure Medicine, Angiotensin-Converting Enzyme Inhibitors, To Prevent Worsening of Kidney Disease Unrelated to Diabetes
Journal: Annals of Internal Medicine (2001)

Summaries for Patients17 July 2001Using a Type of Blood Pressure Medicine, Angiotensin-Converting Enzyme Inhibitors, To Prevent Worsening of Kidney Disease Unrelated to DiabetesSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-135-2-200107170-00003 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail What is the problem and what is known about it so far?Angiotensin-converting enzyme (ACE) inhibitors are a type of medication used to treat high blood pressure. The ACE inhibitors have clearly been shown to prevent worsening of kidney disease caused by diabetes. Some studies suggest that ACE inhibitors benefit nondiabetic people with kidney disease, while other studies do not. More than 350,000 people in the United States have end-stage kidney disease and require either dialysis, a procedure that filters the blood through an artificial kidney machine, several times a week, or a kidney transplant to stay alive. It is ... Author, Article, and Disclosure InformationAffiliations: The summary below is from the full report titled “Angiotensin-Converting Enzyme Inhibitors and Progression of Nondiabetic Renal Disease. A Meta-Analysis of Patient-Level Data.” It is in the 17 July 2001 issue of Annals of Internal Medicine (volume 135, pages 73-87). The authors are TH Jafar, CH Schmid, M Landa, I Giatras, R Toto, G Remuzzi, G Maschio, BM Brenner, A Kamper, P Zucchelli, G Becker, A Himmelmann, K Bannister, P Landais, S Shahinfar, PE de Jong, D de Zeeuw, J Lau, and AS Levey, for the ACE Inhibition in Progressive Renal Disease Study Group.Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians-American Society of Internal Medicine. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoAngiotensin-Converting Enzyme Inhibitors and Progression of Nondiabetic Renal Disease Tazeen H. Jafar , Christopher H. Schmid , Marcia Landa , Ioannis Giatras , Robert Toto , Giuseppe Remuzzi , Giuseppe Maschio , Barry M. Brenner , Annelise Kamper , Pietro Zucchelli , Gavin Becker , Andres Himmelmann , Kym Bannister , Paul Landais , Shahnaz Shahinfar , Paul E. de Jong , Dick de Zeeuw , Joseph Lau , Andrew S. Levey , and Metrics Cited byDevelopment and Analyses of Evaluation Criteria for Meta-analysis-Relationship between Renin-Angiotensin System Inhibitor and Diabetes Mellitus-Pharmacological strategies for kidney function preservation: are there differences by ethnicity? 17 July 2001Volume 135, Issue 2Page: I-21KeywordsACE inhibitorsAngiotensin converting enzyme inhibitorBlood pressureKidneysMedical dialysisProteinsRenal diseasesRenal failureRenal transplantationUrine ePublished: 17 July 2001 Issue Published: 17 July 2001 Copyright & PermissionsCopyright © 2001 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...